Dual-Action PDE4 Inhibitors for COPD Airway Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic obstructive pulmonary disease (COPD) with bronchodilators and anti-inflammatory agents have limitations, including systemic side effects from muscarinic antagonists and mechanism-associated side effects from PDE4 inhibitors, which affect their clinical utility.
Innovation Solution
Development of compounds that act as both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists, designed to provide bronchodilating and anti-inflammatory effects while minimizing systemic side effects through targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If systemically available muscarinic antagonists are used to achieve bronchodilation, then bronchial relaxation is improved, but systemic side effects such as tachycardia and dry mouth occur
Solution Approach 1:
The patent applies local quality by designing inhaled anticholinergic compounds that selectively target airway muscarinic receptors while minimizing systemic absorption. The compounds are formulated for local delivery to the respiratory tract, creating high concentration at the target site with reduced systemic exposure, thereby achieving bronchodilation without proportionate systemic side effects
Solution Approach 2:
The patent uses inhaled delivery as an intermediary mechanism to transport anticholinergic compounds directly to the airways. This delivery system acts as a mediator between the drug and target receptors, enabling localized therapeutic effect while preventing widespread systemic distribution that causes adverse effects like tachycardia
2Ease of operation
If PDE4 inhibitors are used to achieve anti-inflammatory effects, then inflammatory response suppression is improved, but mechanism-associated side effects occur
Solution Approach 1:
The patent merges two therapeutic mechanisms into a single compound: anticholinergic activity for bronchodilation and PDE4 inhibition for anti-inflammatory effects. This combination approach allows simultaneous delivery of both activities through one inhaled compound, potentially reducing the need for multiple medications and their associated side effect profiles
Solution Approach 2:
The patent creates multi-functional compounds that simultaneously exhibit both antimuscarinic and PDE4 inhibitory activities. These dual-action compounds address multiple pathophysiological pathways in COPD (bronchodilation and inflammation) with a single agent, improving ease of treatment while potentially reducing overall side effect burden
3Reliability
If dual-action compounds are used to combine bronchodilating and anti-inflammatory effects, then therapeutic efficacy is improved, but compound complexity increases
Solution Approach 1:
The patent combines two distinct pharmacological activities (antimuscarinic and PDE4 inhibition) into single molecular structures. By merging these functions at the molecular level rather than using combination therapy, the patent achieves reliable dual efficacy while simplifying the treatment regimen, despite the increased molecular complexity of the compounds
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds offer a new class of drugs that combine bronchodilating and anti-inflammatory properties, potentially improving lung function and reducing exacerbations in COPD with a more favorable therapeutic window, reducing systemic side effects.
Implementation Method 1
PDE4 is the predominant PDE expressed in neutrophils and T cells, suggesting that PDE4 inhibitors would be effective in controlling inflammation in COPD. Inhibition of PDE4 in inflammatory cells influences various specific responses, such as the production and/or release of pro-inflammatory mediators including cytokines and reactive oxygen species
Implementation Method 2
Muscarinic antagonists block the effects of ACh at muscarinic receptors. Postsynaptic M3 receptors are known to mediate both contraction of smooth muscle in the respiratory tract and mucus secretion, making them a major target for symptomatic relief of COPD
Data Source
AI summary
The invention relates to novel compounds which are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.